TISIDB

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Ceroid-lipofuscinosis neuronal protein 5, secreted form: Lysosome ; SUBCELLULAR LOCATION: Ceroid-lipofuscinosis neuronal protein 5: Membrane Single-pass type II membrane protein Note=An amphipathic anchor region facilitates its association with the membrane.
Domain	PF15014 Ceroid-lipofuscinosis neuronal protein 5
Function	Plays a role in influencing the retrograde trafficking of lysosomal sorting receptors SORT1 and IGF2R from the endosomes to the trans-Golgi network by controlling the recruitment of retromer complex to the endosomal membrane. Regulates the localization and activation of RAB7A which is required to recruit the retromer complex to the endosomal membrane (PubMed:22431521).

> Gene Ontology [ TOP ]
Biological Process	GO:0006465 signal peptide processing GO:0006885 regulation of pH GO:0007033 vacuole organization GO:0007034 vacuolar transport GO:0007035 vacuolar acidification GO:0007040 lysosome organization GO:0007042 lysosomal lumen acidification GO:0016197 endosomal transport GO:0016482 cytosolic transport GO:0016485 protein processing GO:0021700 developmental maturation GO:0030004 cellular monovalent inorganic cation homeostasis GO:0030641 regulation of cellular pH GO:0035751 regulation of lysosomal lumen pH GO:0042147 retrograde transport, endosome to Golgi GO:0042551 neuron maturation GO:0045851 pH reduction GO:0048469 cell maturation GO:0051098 regulation of binding GO:0051099 positive regulation of binding GO:0051452 intracellular pH reduction GO:0051453 regulation of intracellular pH GO:0051604 protein maturation GO:0055067 monovalent inorganic cation homeostasis GO:0070085 glycosylation GO:0080171 lytic vacuole organization GO:1904424 regulation of GTP binding GO:1904426 positive regulation of GTP binding
Molecular Function	GO:0005537 mannose binding GO:0030246 carbohydrate binding GO:0048029 monosaccharide binding
Cellular Component	GO:0005765 lysosomal membrane GO:0098852 lytic vacuole membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04142 Lysosome
Reactome	-

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CLN5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CLN5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CLN5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.586	0.0333
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.614	0.739
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.566	0.676
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.268	0.27
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.543	0.714
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.08	0.965
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.148	0.679
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.143	0.928
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.172	0.923
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.362	0.788
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.169	0.932
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.115	0.116

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CLN5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CLN5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CLN5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CLN5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CLN5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CLN5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CLN5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CLN5
Name	ceroid-lipofuscinosis, neuronal 5
Aliases	Protein CLN5; Ceroid-lipofuscinosis neuronal protein 5
Chromosomal Location	13q21.2-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CLN5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CLN5